Liste des publications sur les maladies auto-immunes du CRMR RESO de Strasbourg

Le CRMR RESO de Strasbourg assure une très importante activité de recherche scientifique fondamentale, translationnelle et clinique donnant lieu à de très nombreuses publications nationales et internationales de premier plan dans le domaine des maladies auto-immunes et des maladies immunologiques rares. Ces publications ont un très fort retentissement pour la prise en charge diagnostique et thérapeutique des patients.

Liste des publications du CRMR RESO (250 dernières publications)

1.            Wienke J, Bellutti Enders F, Lim J, et al. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation. Arthritis & rheumatology (Hoboken, NJ). 2019.

2.            Traineau H, Aggarwal R, Monfort JB, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. Journal of the American Academy of Dermatology. 2019.

3.            Spielmann L, Nespola B, Severac F, et al. Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Annals of the rheumatic diseases. 2019;78(8):1101-1106.

4.            Souberbielle JC, Cormier C, Cavalier E, et al. Vitamin D Supplementation in France in patients with or at risk for osteoporosis: Recent data and new practices. Joint, bone, spine : revue du rhumatisme. 2019.

5.            Smith N, Rodero MP, Bekaddour N, et al. Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for lupus treatment. Science advances. 2019;5(7):eaav9019.

6.            Sibilia J. [Periodic certification of physicians for personalized professional development]. La Revue du praticien. 2019;69(2):135-136.

7.            Sebbag E, Felten R, Sagez F, Sibilia J, Devilliers H, Arnaud L. The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database. Annals of the rheumatic diseases. 2019;78(6):844-848.

8.            Schleiss C, Ilias W, Tahar O, et al. BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. Scientific reports. 2019;9(1):701.

9.            Sanosyan A, Daien C, Nutz A, et al. Discrepancy of Serological and Molecular Patterns of Circulating Epstein-Barr Virus Reactivation in Primary Sjogren’s Syndrome. Frontiers in immunology. 2019;10:1153.

10.          Rouyer O, Auger C, Charles AL, et al. Effects of a High Fat Meal Associated with Water, Juice, or Champagne Consumption on Endothelial Function and Markers of Oxidative Stress and Inflammation in Young, Healthy Subjects. Journal of clinical medicine. 2019;8(6).

11.          Rinagel M, Chatelus E, Jousse-Joulin S, et al. Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. Autoimmunity reviews. 2019;18(1):56-61.

12.          Rinagel M, Chatelus E, Arnaud L, Jousse-Joulin S. [Contribution of Doppler ultrasound for the diagnosis of giant cell arteritis]. Presse medicale (Paris, France : 1983). 2019.

13.          Poindron V, Chatelus E, Canuet M, et al. T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. Seminars in arthritis and rheumatism. 2019.

14.          Pijnenburg L, Lipsker D, Mallick A, Proust F, Arnaud L, Javier RM. Cervical myelopathy revealing a unique case of retinoid hyperostosis. Joint, bone, spine : revue du rhumatisme. 2019.

15.          Paradis S, Charles AL, Georg I, et al. Aging Exacerbates Ischemia-Reperfusion-Induced Mitochondrial Respiration Impairment in Skeletal Muscle. Antioxidants (Basel, Switzerland). 2019;8(6).

16.          Nguyen MVC, Adrait A, Baillet A, Trocme C, Gottenberg JE, Gaudin P. Identification of cartilage oligomeric matrix protein as biomarker predicting abatacept response in rheumatoid arthritis patients with insufficient response to a first anti-TNFalpha treatment. Joint, bone, spine : revue du rhumatisme. 2019;86(3):401-403.

17.          Mouasni S, Gonzalez V, Schmitt A, et al. The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding. Cell death & disease. 2019;10(3):190.

18.          Meyer E, Labani A, Schaeffer M, et al. Wide-volume versus helical acquisition in unenhanced chest CT: prospective intra-patient comparison of diagnostic accuracy and radiation dose in an ultra-low-dose setting. European radiology. 2019.

19.          Meyer A, Sibilia J. Strategy for suspected myositis. Joint, bone, spine : revue du rhumatisme. 2019.

20.          Messer L, Duret PM, Mallick A, Willaume T, Spielmann L, Chatelus E. Single tumor-like tophus. Joint, bone, spine : revue du rhumatisme. 2019;86(4):509-510.

21.          Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. The Journal of allergy and clinical immunology. 2019;143(1):433-436.

22.          Mertz P, Belot A, Cervera R, et al. The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. Joint, bone, spine : revue du rhumatisme. 2019;86(3):363-368.

23.          Matuszak J, Blondet C, Hubele F, et al. Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology (Oxford, England). 2019.

24.          Magalon J, Velier M, Simoncini S, et al. Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. Annals of the rheumatic diseases. 2019;78(3):391-398.

25.          Luxembourger C, Ruyssen-Witrand A, Ladhari C, et al. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. The pharmacogenomics journal. 2019;19(4):368-374.

26.          Lespessailles E, Paccou J, Javier RM, Thomas T, Cortet B. Obesity, bariatric surgery and fractures. The Journal of clinical endocrinology and metabolism. 2019.

27.          Leardini-Tristao M, Charles AL, Lejay A, et al. Beneficial Effect of Exercise on Cognitive Function during Peripheral Arterial Disease: Potential Involvement of Myokines and Microglial Anti-Inflammatory Phenotype Enhancement. Journal of clinical medicine. 2019;8(5).

28.          Kostine M, Cappelli LC, Calabrese C, et al. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Annals of the rheumatic diseases. 2019;78(6):860-862.

29.          Guillaume-Jugnot P, Badoglio M, Labopin M, et al. Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Clinical rheumatology. 2019;38(5):1501-1511.

30.          Guffroy A, Dieudonne Y, Uring-Lambert B, Goetz J, Alembik Y, Korganow AS. Infection risk among adults with down syndrome: a two group series of 101 patients in a tertiary center. Orphanet journal of rare diseases. 2019;14(1):15.

31.          Grimaud F, Yelnik C, Pineton de Chambrun M, et al. Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. Rheumatology (Oxford, England). 2019;58(6):1006-1010.

32.          Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Seminars in arthritis and rheumatism. 2019;48(6):1105-1112.

33.          Gottenberg JE, Morel J, Perrodeau E, et al. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ (Clinical research ed). 2019;364:l67.

34.          Gossec L, Soubrier M, Foissac F, et al. Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. RMD open. 2019;5(2):e000914.

35.          Gossec L, Fayet F, Soubrier M, et al. Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. Rheumatology (Oxford, England). 2019;58(8):1498-1499.

36.          Gorlier C, Gottenberg JE, Laurans L, Simon T, Ait-Oufella H, Sellam J. Serum level of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is a biomarker of synovitis in rheumatoid arthritis. International journal of rheumatic diseases. 2019.

37.          Frantzen L, Cohen JD, Trope S, et al. Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Joint, bone, spine : revue du rhumatisme. 2019;86(4):491-496.

38.          Fox RI, Fox CM, Gottenberg JE, Dorner T. Treatment of Sjogren’s syndrome: current therapy and future directions. Rheumatology (Oxford, England). 2019.

39.          Felten R, Scher F, Sibilia J, Gottenberg JE, Arnaud L. The pipeline of targeted therapies under clinical development for primary Sjogren’s syndrome: A systematic review of trials. Autoimmunity reviews. 2019;18(6):576-582.

40.          Felten R, Scher F, Sibilia J, Chasset F, Arnaud L. Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. Joint, bone, spine : revue du rhumatisme. 2019;86(4):429-436.

41.          Felten R, Scher F, Sagez F, Chasset F, Arnaud L. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug design, development and therapy. 2019;13:1535-1543.

42.          Felten R, Sagez F, Gavand PE, et al. 10 most important contemporary challenges in the management of SLE. Lupus science & medicine. 2019;6(1):e000303.

43.          Felten R, Perrin P, Caillard S, Moulin B, Javier RM. Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism. PloS one. 2019;14(2):e0212931.

44.          Felten J, Cogne K, Fischbach-Boulanger C, et al. Atypical Right Pulmonary Artery Dissection Complicating Severe Blunt Chest Trauma. Seminars in thoracic and cardiovascular surgery. 2019;31(1):137-139.

45.          Durel CA, Hot A, Trefond L, et al. Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford, England). 2019.

46.          Dieudonne Y, Guffroy A, Vollmer O, Carapito R, Korganow AS. IKZF1 Loss-of-Function Variant Causes Autoimmunity and Severe Familial Antiphospholipid Syndrome. Journal of clinical immunology. 2019;39(4):353-357.

47.          Dieudonne Y, Gies V, Guffroy A, et al. Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. Journal of autoimmunity. 2019;102:150-158.

48.          Delaval L, Daumas A, Samson M, et al. Large-vessel vasculitis diagnosed between 50 and 60years: Case-control study based on 183 cases and 183 controls aged over 60years. Autoimmunity reviews. 2019;18(7):714-720.

49.          Daste C, Rannou F, Mouthon L, et al. Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. Seminars in arthritis and rheumatism. 2019;48(4):694-700.

50.          Chasset F, Richez C, Martin T, Belot A, Korganow AS, Arnaud L. Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers). Joint, bone, spine : revue du rhumatisme. 2019;86(2):165-171.

51.          Bykerk VP, Ostor AJK, Alvaro-Gracia J, et al. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice. Clinical rheumatology. 2019.

52.          Briot K, Paccou J, Beuzeboc P, et al. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Joint, bone, spine : revue du rhumatisme. 2019;86(1):21-28.

53.          Bouis D, Kirstetter P, Arbogast F, et al. Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice. The Journal of allergy and clinical immunology. 2019;143(2):712-725.e715.

54.          Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjogren’s syndrome in the JOQUER randomized trial. Rheumatology (Oxford, England). 2019.

55.          Berthelot JM, Sibilia J. Trained Immunity and Autoimmune Disease: Did Eve Sin before Adam? Joint, bone, spine : revue du rhumatisme. 2019;86(3):293-295.

56.          Beauvais C, Rodere M, Pereira B, et al. Essential knowledge for patients with rheumatoid arthritis or spondyloarthritis: Results of a multicentric survey in France among health professionals and patients. Joint, bone, spine : revue du rhumatisme. 2019.

57.          Aussy A, Freret M, Gallay L, et al. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1gamma Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis & rheumatology (Hoboken, NJ). 2019.

58.          Arnaud L, Mertz P, Gavand PE, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Annals of the rheumatic diseases. 2019;78(4):504-508.

59.          Arnaud L, Lebrun-Vignes B, Salem JE. Checkpoint inhibitor-associated immune arthritis. Annals of the rheumatic diseases. 2019;78(7):e68.

60.          Arnaud L, Gavand PE, Voll R, et al. Predictors of fatigue and severe fatigue in a large international cohort of patients with systemic lupus erythematosus and a systematic review of the literature. Rheumatology (Oxford, England). 2019;58(6):987-996.

61.          Anquetil C, Hachulla E, Machuron F, et al. Is early-onset primary Sjogren’s syndrome a worse prognosis form of the disease? Rheumatology (Oxford, England). 2019;58(7):1163-1167.

62.          Aguiar F, Brito I, Sibilia J. Revisiting the Association Between Systemic Lupus Erythematosus and Gout. Reumatologia clinica. 2019.

63.          Wilhelm M, Wang F, Schall N, et al. Lupus Regulator Peptide P140 Represses B Cell Differentiation by Reducing HLA Class II Molecule Overexpression. Arthritis & rheumatology (Hoboken, NJ). 2018;70(7):1077-1088.

64.          Terreaux W, Masson C, Eschard JP, et al. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE. Joint, bone, spine : revue du rhumatisme. 2018;85(1):53-57.

65.          Tamirou F, Arnaud L, Talarico R, et al. Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD open. 2018;4(2):e000793.

66.          Taillandier A, Domingues C, Dufour A, et al. Genetic analysis of adults heterozygous for ALPL mutations. Journal of bone and mineral metabolism. 2018;36(6):723-733.

67.          Soubrier M, Lambert C, Combe B, et al. A randomised, double-blind, placebo-controlled study assessing the efficacy of high doses of vitamin D on functional disability in patients with rheumatoid arthritis. Clinical and experimental rheumatology. 2018;36(6):1056-1060.

68.          Simoni L, Delgado V, Ruer-Laventie J, et al. Trib1 Is Overexpressed in Systemic Lupus Erythematosus, While It Regulates Immunoglobulin Production in Murine B Cells. Frontiers in immunology. 2018;9:373.

69.          Sibilia J. [Research training: a major challenge for future MDs]. Medecine sciences : M/S. 2018;34(5):375-376.

70.          Siala M, Rihl M, Sellami H, et al. Detection of Shigella spp. nucleic acids in the synovial tissue of Tunisian rheumatoid arthritis patients and other forms of arthritis by quantitative real-time polymerase chain reaction. Rheumatology international. 2018;38(6):1009-1016.

71.          Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. American journal of hematology. 2018;93(3):424-429.

72.          Sawaf M, Fauny JD, Felten R, et al. Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells. JCI insight. 2018;3(13).

73.          Salmon JH, Perotin JM, Morel J, et al. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology (Oxford, England). 2018;57(1):134-139.

74.          Sali E, Hardy A, Grimaud O, Meyer A. An original all-arthroscopic technique for bony fixation of lateral meniscus allograft via four tibial tunnels: A cadaver study. Orthopaedics & traumatology, surgery & research : OTSR. 2018;104(8):1205-1208.

75.          Romao VC, Talarico R, Scire CA, et al. Sjogren’s syndrome: state of the art on clinical practice guidelines. RMD open. 2018;4(Suppl 1):e000789.

76.          Riviere E, Sellam J, Pascaud J, Ravaud P, Gottenberg JE, Mariette X. Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. Arthritis research & therapy. 2018;20(1):122.

77.          Rietveld A, van den Hoogen LL, Bizzaro N, et al. Autoantibodies to Cytosolic 5′-Nucleotidase 1A in Primary Sjogren’s Syndrome and Systemic Lupus Erythematosus. Frontiers in immunology. 2018;9:1200.

78.          Rednic S, Damian L, Talarico R, et al. Relapsing polychondritis: state of the art on clinical practice guidelines. RMD open. 2018;4(Suppl 1):e000788.

79.          Pottecher J, Adamopoulos C, Lejay A, et al. Diabetes Worsens Skeletal Muscle Mitochondrial Function, Oxidative Stress, and Apoptosis After Lower-Limb Ischemia-Reperfusion: Implication of the RISK and SAFE Pathways? Frontiers in physiology. 2018;9:579.

80.          Oishi S, Wendling D, Sibilia J, et al. Treatment of active rheumatoid arthritis: comparison of patients younger vs older than 75 years (CORPUS cohort). Human vaccines & immunotherapeutics. 2018;14(11):2612-2617.

81.          Nehmar R, Mariotte A, de Cauwer A, Sibilia J, Bahram S, Georgel P. Therapeutic Perspectives for Interferons and Plasmacytoid Dendritic Cells in Rheumatoid Arthritis. Trends in molecular medicine. 2018;24(4):338-347.

82.          Moulis G, Pugnet G, Costedoat-Chalumeau N, et al. Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Annals of the rheumatic diseases. 2018;77(8):1172-1178.

83.          Meyer A, Scire CA, Talarico R, et al. Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]. RMD open. 2018;4(Suppl 1):e000784.

84.          Meyer A, Laverny G, Bernardi L, et al. Mitochondria: An Organelle of Bacterial Origin Controlling Inflammation. Frontiers in immunology. 2018;9:536.

85.          Meyer A, Lannes B, Goetz J, et al. Inflammatory myopathies: A new landscape. Joint, bone, spine : revue du rhumatisme. 2018;85(1):23-33.

86.          Messer L, Sibilia J, Miazhiom ACL. Diagnostic uncertainty and clinical decision-making strategies. Joint, bone, spine : revue du rhumatisme. 2018;85(3):267-269.

87.          Mertz P, Herber M, Jeannel J, Korganow AS, Guffroy A. Persistent Acrocyanosis-A Rare Manifestation Revealing Anti-PL-12 Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2018;70(10):1698.

88.          Mekinian A, Resche-Rigon M, Comarmond C, et al. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. Journal of autoimmunity. 2018;91:55-60.

89.          Marteau P, Adamsbaum C, Rossi-Semerano L, et al. Conventional radiography in juvenile idiopathic arthritis: Joint recommendations from the French societies for rheumatology, radiology and paediatric rheumatology. European radiology. 2018;28(9):3963-3976.

90.          Mariampillai K, Granger B, Amelin D, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA neurology. 2018;75(12):1528-1537.

91.          Lourdudoss C, Arnaud L, Wolk A, van Vollenhoven RF, Di Giuseppe D. Long-Term Dietary Changes after Diagnosis of Rheumatoid Arthritis in Swedish Women: Data from a Population-Based Cohort. International journal of rheumatology. 2018;2018:9152480.

92.          Lebrun D, Mestrallet S, Dehoux M, et al. Validation of the Fautrel classification criteria for adult-onset Still’s disease. Seminars in arthritis and rheumatism. 2018;47(4):578-585.

93.          Le Besnerais M, Arnaud L, Boutemy J, et al. Aortic involvement in relapsing polychondritis. Joint, bone, spine : revue du rhumatisme. 2018;85(3):345-351.

94.          Juge PA, Lee JS, Ebstein E, et al. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. The New England journal of medicine. 2018;379(23):2209-2219.

95.          Jardel S, Puechal X, Le Quellec A, et al. Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. Autoimmunity reviews. 2018;17(7):653-659.

96.          Henry J, Gottenberg JE, Rouanet S, et al. Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. Rheumatology (Oxford, England). 2018;57(3):538-547.

97.          Harris VM, Sharma R, Cavett J, et al. Corrigendum to “Klinefelter’s syndrome (47,XXY) is in excess among men with Sjogren’s syndrome” [Clin. Immunol. 168 (2016) 25-29]. Clinical immunology (Orlando, Fla). 2018;187:137-138.

98.          Guffroy A, Martin T, Korganow AS. Adolescents and young adults (AYAs) affected by chronic immunological disease: A tool-box for success during the transition to adult care. Clinical immunology (Orlando, Fla). 2018;197:198-204.

99.          Gottenberg JE, Dorner T, Bootsma H, et al. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjogren’s Syndrome: Post Hoc Analyses From the EMBODY Trials. Arthritis & rheumatology (Hoboken, NJ). 2018;70(5):763-773.

100.        Gies V, Schickel JN, Jung S, et al. Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI insight. 2018;3(5).

101.        Gabay C, Fautrel B, Rech J, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Annals of the rheumatic diseases. 2018;77(6):840-847.

102.        Fogel O, Riviere E, Seror R, et al. Role of the IL-12/IL-35 balance in patients with Sjogren syndrome. The Journal of allergy and clinical immunology. 2018;142(1):258-268.e255.

103.        Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmunity reviews. 2018;17(8):781-790.

104.        De Cauwer A, Mariotte A, Sibilia J, Bahram S, Georgel P. DICER1: A Key Player in Rheumatoid Arthritis, at the Crossroads of Cellular Stress, Innate Immunity, and Chronic Inflammation in Aging. Frontiers in immunology. 2018;9:1647.

105.        Couture P, Brillet PY, Varin S, et al. Sarcoidosis in Patients with Antisynthetase Syndrome: Presentation and Outcome. The Journal of rheumatology. 2018;45(9):1296-1300.

106.        Collet C, Ostertag A, Ricquebourg M, et al. Primary Osteoporosis in Young Adults: Genetic Basis and Identification of Novel Variants in Causal Genes. JBMR plus. 2018;2(1):12-21.

107.        Chasset F, Tounsi T, Cesbron E, Barbaud A, Frances C, Arnaud L. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2018;78(2):342-350.e344.

108.        Chasset F, Arnaud L, Jachiet M, et al. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. Journal of the American Academy of Dermatology. 2018;78(1):107-114.e101.

109.        Chasset F, Arnaud L, Frances C. Thromboprophylaxis and thalidomide in the noncancer setting: Toward an algorithm that is based on patient risk factors and underlying disease? Journal of the American Academy of Dermatology. 2018;79(3):e47-e48.

110.        Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmunity reviews. 2018;17(1):44-52.

111.        Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the rheumatic diseases. 2018;77(8):1143-1149.

112.        Cesbron E, Bessis D, Jachiet M, et al. Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. Journal of the American Academy of Dermatology. 2018;79(1):162-165.

113.        Carapito R, Carapito C, Morlon A, et al. Multi-OMICS analyses unveil STAT1 as a potential modifier gene in mevalonate kinase deficiency. Annals of the rheumatic diseases. 2018;77(11):1675-1687.

114.        Brito-Zeron P, Acar-Denizli N, Ng WF, et al. How immunological profile drives clinical phenotype of primary Sjogren’s syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project). Clinical and experimental rheumatology. 2018;36 Suppl 112(3):102-112.

115.        Bitoun S, Miceli-Richard C, Verstuyft C, et al. Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. Annals of the rheumatic diseases. 2018;77(12):1835-1836.

116.        Belizna C, Stojanovich L, Cohen-Tervaert JW, et al. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? Autoimmunity reviews. 2018;17(8):739-745.

117.        Belizna C, Pregnolato F, Abad S, et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity reviews. 2018;17(12):1153-1168.

118.        van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the rheumatic diseases. 2017;76(3):554-561.

119.        Tiffreau V, Rannou F, Kopciuch F, et al. Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial. Archives of physical medicine and rehabilitation. 2017;98(2):227-234.

120.        Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases. 2017;76(6):960-977.

121.        Sharma R, Harris VM, Cavett J, et al. Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjogren’s Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2017;69(11):2187-2192.

122.        Sanges S, Riviere S, Mekinian A, et al. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Autoimmunity reviews. 2017;16(4):377-384.

123.        Riviere E, Arnaud L, Ebbo M, et al. Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. The Journal of rheumatology. 2017;44(7):1011-1017.

124.        Rezaei H, Af Klint E, Hammer HB, et al. Analysis of correlation and causes for discrepancy between quantitative and semi-quantitative Doppler scores in synovitis in rheumatoid arthritis. Rheumatology (Oxford, England). 2017;56(2):255-262.

125.        Rat AC, Fautrel B, Flipon E, et al. Factors associated with knowledge and safety skills of arthritis patients receiving biologics: A survey of 677 patients. Joint, bone, spine : revue du rhumatisme. 2017;84(2):163-168.

126.        Rannou F, Boutron I, Mouthon L, et al. Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. Arthritis care & research. 2017;69(7):1050-1059.

127.        Qi S, Barnig C, Charles AL, et al. Effect of nasal allergen challenge in allergic rhinitis on mitochondrial function of peripheral blood mononuclear cells. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2017;118(3):367-369.

128.        Pugnet G, Castilla-Llorente C, Puyade M, et al. [Indications and follow-up for autologous hematopoietic stem cell transplantation in autoimmune and autoinflammatory diseases: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bulletin du cancer. 2017;104(12s):S169-s180.

129.        Platten M, Kisten Y, Kalvesten J, Arnaud L, Forslind K, van Vollenhoven R. Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA. RMD open. 2017;3(1):e000369.

130.        Petit H, Marcellin L, Chatelus E. Lumbar Spine Chondrocalcinosis. The Journal of rheumatology. 2017;44(8):1288-1289.

131.        Perrin P, Kiener C, Javier RM, et al. Recent Changes in Chronic Kidney Disease-Mineral and Bone Disorders and Associated Fractures After Kidney Transplantation. Transplantation. 2017;101(8):1897-1905.

132.        Parodis I, Sjowall C, Jonsen A, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmunity reviews. 2017;16(4):343-351.

133.        Nourisson C, Soubrier M, Mulliez A, et al. Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the ‘ORA’ registry. RMD open. 2017;3(2):e000515.

134.        Nehmar R, Alsaleh G, Voisin B, et al. Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis. Arthritis & rheumatology (Hoboken, NJ). 2017;69(11):2124-2135.

135.        Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford, England). 2017;56(10):1746-1754.

136.        Meyer A, Laverny G, Allenbach Y, et al. IFN-beta-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta neuropathologica. 2017;134(4):655-666.

137.        Mercer LK, Regierer AC, Mariette X, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the rheumatic diseases. 2017;76(12):2025-2030.

138.        Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the rheumatic diseases. 2017;76(2):386-391.

139.        Lopez A, Mariette X, Bachelez H, et al. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. Journal of autoimmunity. 2017;80:10-27.

140.        Lazzaroni MG, Cavazzana I, Colombo E, et al. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. The Journal of rheumatology. 2017;44(5):639-647.

141.        Latourte A, Gottenberg JE, Luxembourger C, et al. Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology (Oxford, England). 2017;56(4):629-637.

142.        Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity reviews. 2017;16(6):650-657.

143.        Juge PA, Gazal S, Constantin A, et al. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD open. 2017;3(2):e000448.

144.        Juge PA, Borie R, Kannengiesser C, et al. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. The European respiratory journal. 2017;49(5).

145.        Iannone F, Courvoisier DS, Gottenberg JE, et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA). Clinical rheumatology. 2017;36(4):773-779.

146.        Hengen M, Willemain R, Meyer A, Langer B, Joshi GP, Diemunsch P. Transnasal Humidified Rapid-Insufflation Ventilatory Exchange for Preoxygenation Before Cesarean Delivery Under General Anesthesia: A Case Report. A & A case reports. 2017;9(7):216-218.

147.        Hardy A, Casabianca L, Hardy E, Grimaud O, Meyer A. Combined reconstruction of the anterior cruciate ligament associated with anterolateral tenodesis effectively controls the acceleration of the tibia during the pivot shift. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA. 2017;25(4):1117-1124.

148.        Guillaume-Czitrom S, Sibilia J, Nordal E. Growing up with chronic arthritis: the confusing matter of classification. RMD open. 2017;3(1):e000417.

149.        Guffroy A, Mourot-Cottet R, Gerard L, et al. Neutropenia in Patients with Common Variable Immunodeficiency: a Rare Event Associated with Severe Outcome. Journal of clinical immunology. 2017;37(7):715-726.

150.        Guffroy A, Dervieux B, Gravier S, et al. Systemic capillary leak syndrome and autoimmune diseases: A case series. Seminars in arthritis and rheumatism. 2017;46(4):509-512.

151.        Glauzy S, Sng J, Bannock JM, et al. Defective Early B Cell Tolerance Checkpoints in Sjogren’s Syndrome Patients. Arthritis & rheumatology (Hoboken, NJ). 2017;69(11):2203-2208.

152.        Gies V, Wagner A, Seifert C, et al. Identification of autoreactive B cells with labeled nucleosomes. Scientific reports. 2017;7(1):602.

153.        Gies V, Guffroy A, Korganow AS. [Thymic B cells: not simple bystanders of T cell lymphopoiesis]. Medecine sciences : M/S. 2017;33(8-9):771-778.

154.        Gies V, Guffroy A, Danion F, et al. B cells differentiate in human thymus and express AIRE. The Journal of allergy and clinical immunology. 2017;139(3):1049-1052.e1012.

155.        Gies V, Bouis D, Martin M, et al. Phenotyping of autoreactive B cells with labeled nucleosomes in 56R transgenic mice. Scientific reports. 2017;7(1):13232.

156.        Gavand PE, Serio I, Arnaud L, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmunity reviews. 2017;16(7):743-749.

157.        Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Annals of the rheumatic diseases. 2017;76(11):1897-1905.

158.        Duquenne C, Wendling D, Sibilia J, et al. Glucocorticoid-sparing effect of first-year anti-TNFalpha treatment in rheumatoid arthritis (CORPUS Cohort). Clinical and experimental rheumatology. 2017;35(4):638-646.

159.        de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers. Joint, bone, spine : revue du rhumatisme. 2017;84(2):133-140.

160.        Danion F, Sparsa L, Arnaud L, et al. Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD open. 2017;3(2):e000555.

161.        Cornec D, Devauchelle-Pensec V, Mariette X, et al. Severe Health-Related Quality of Life Impairment in Active Primary Sjogren’s Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. Arthritis care & research. 2017;69(4):528-535.

162.        Colin de Verdiere S, Noel E, Lozano C, et al. Respiratory Complications Lead to the Diagnosis of Chronic Granulomatous Disease in Two Adult Patients. Journal of clinical immunology. 2017;37(2):113-116.

163.        Choy E, Aletaha D, Behrens F, et al. Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis. Rheumatology (Oxford, England). 2017;56(5):689-697.

164.        Charles AL, Guilbert AS, Guillot M, et al. Muscles Susceptibility to Ischemia-Reperfusion Injuries Depends on Fiber Type Specific Antioxidant Level. Frontiers in physiology. 2017;8:52.

165.        Carapito R, Gottenberg JE, Kotova I, et al. A new MHC-linked susceptibility locus for primary Sjogren’s syndrome: MICA. Human molecular genetics. 2017;26(13):2565-2576.

166.        Brito-Zeron P, Acar-Denizli N, Zeher M, et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjogren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjogren Project Consortium. Annals of the rheumatic diseases. 2017;76(6):1042-1050.

167.        Bienvenu B, Aouba A, Gottenberg JE, Verstuyft C. Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system. Current medical research and opinion. 2017;33(4):605-611.

168.        Benyamine A, Magalon J, Cointe S, et al. Increased serum levels of fractalkine and mobilisation of CD34(+)CD45(-) endothelial progenitor cells in systemic sclerosis. Arthritis research & therapy. 2017;19(1):60.

169.        Beck M, Michel B, Rybarczyk-Vigouret MC, et al. Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey. mAbs. 2017;9(2):383-390.

170.        Arnaud L, Nordin A, Lundholm H, et al. Effect of Corticosteroids and Cyclophosphamide on Sex Hormone Profiles in Male Patients With Systemic Lupus Erythematosus or Systemic Sclerosis. Arthritis & rheumatology (Hoboken, NJ). 2017;69(6):1272-1279.

171.        Arnaud L, Conti F, Massaro L, Denas G, Chasset F, Pengo V. Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro’s and Con’s. Autoimmunity reviews. 2017;16(11):1103-1108.

172.        Andres E, Mourot-Cottet R, Maloisel F, Vogel T, Tebacher M, Gottenberg JE. History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg’s agranulocytosis cohort. European journal of internal medicine. 2017;46:e13-e14.

173.        Andres E, Mourot-Cottet R, Maloisel F, et al. Idiosyncratic drug-induced neutropenia & agranulocytosis. QJM : monthly journal of the Association of Physicians. 2017.

174.        Andres E, Mourot-Cottet R, Maloisel F, et al. History and Outcome of Febrile Neutropenia Outside the Oncology Setting: A Retrospective Study of 76 Cases Related to Non-Chemotherapy Drugs. Journal of clinical medicine. 2017;6(10).

175.        Truchetet ME, Poursac N, Barnetche T, et al. Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry. Arthritis research & therapy. 2016;18:72.

176.        Souberbielle JC, Benhamou CL, Cortet B, et al. French law: what about a reasoned reimbursement of serum vitamin D assays? Geriatrie et psychologie neuropsychiatrie du vieillissement. 2016;14(4):377-382.

177.        Seror R, Meiners P, Baron G, et al. Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the rheumatic diseases. 2016;75(11):1945-1950.

178.        Seror R, Boudaoud S, Pavy S, et al. Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. Scientific reports. 2016;6:18421.

179.        Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren’s syndrome with EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the rheumatic diseases. 2016;75(2):382-389.

180.        Reygaerts T, Arnaud L, Devilliers H. Survival Analysis Is Preferable to a Count of Events When Assessing the Effects of Tobacco Exposure in Systemic Lupus Erythematosus: Comment on the Article by Montes et al. Arthritis & rheumatology (Hoboken, NJ). 2016;68(4):1046-1047.

181.        Picard C, Vincent T, Lega JC, et al. Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study. Immunologic research. 2016;64(3):677-686.

182.        Parodis I, Arnaud L, Gerhardsson J, et al. Antiphospholipid Antibodies in Lupus Nephritis. PloS one. 2016;11(6):e0158076.

183.        Paradis S, Charles AL, Meyer A, et al. Chronology of mitochondrial and cellular events during skeletal muscle ischemia-reperfusion. American journal of physiology Cell physiology. 2016;310(11):C968-982.

184.        Nocturne G, Tarn J, Boudaoud S, et al. Germline variation of TNFAIP3 in primary Sjogren’s syndrome-associated lymphoma. Annals of the rheumatic diseases. 2016;75(4):780-783.

185.        Muff G, Dufour S, Meyer A, et al. Comparative assessment of knee extensor and flexor muscle strength measured using a hand-held vs. isokinetic dynamometer. Journal of physical therapy science. 2016;28(9):2445-2451.

186.        Mourot-Cottet R, Maloisel F, Severac F, et al. Idiosyncratic Drug-Induced Severe Neutropenia and Agranulocytosis in Elderly Patients (>/=75 years): A Monocentric Cohort Study of 61 Cases. Drugs – real world outcomes. 2016;3(4):393-399.

187.        Moulis G, Audemard-Verger A, Arnaud L, et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. Autoimmunity reviews. 2016;15(3):203-209.

188.        Morel J, Czitrom SG, Mallick A, Sellam J, Sibilia J. Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. Joint, bone, spine : revue du rhumatisme. 2016;83(2):135-141.

189.        Meyer A, Lannes B, Garnon J, Hoenen-Clavert V, Geny B, Sibilia J. Muscle MRI: All that glitters is not myositis. Joint, bone, spine : revue du rhumatisme. 2016;83(3):349.

190.        Meyer A, Chifflot H, Chatelus E, et al. Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast Region. Arthritis & rheumatology (Hoboken, NJ). 2016;68(7):1731-1737.

191.        Meyer A, Alsaleh G, Heuschling C, et al. Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling. RMD open. 2016;2(2):e000294.

192.        Messer L, Alsaleh G, Georgel P, et al. Homozygosity for the V377I mutation in mevalonate kinase causes distinct clinical phenotypes in two sibs with hyperimmunoglobulinaemia D and periodic fever syndrome (HIDS). RMD open. 2016;2(1):e000196.

193.        Matuszak J, Durckel J, Sibilia J, Lipsker D, Blondet C, Imperiale A. Is Sarcoid Dactylitis Worse Than We ExPEcT? Arthritis & rheumatology (Hoboken, NJ). 2016;68(2):417.

194.        Martin M, Lipsker D, Fornecker LM, Toussaint E, Martin T. Bendamustine conditioning for refractory type I cryoglobulinemia. Joint, bone, spine : revue du rhumatisme. 2016;83(5):591-592.

195.        Margerin F, Gottenberg JE, Lipsker D. Occurrence of Rheumatoid Arthritis in a Patient Treated with Anakinra for Schnitzler Syndrome: A Case Report. The Journal of rheumatology. 2016;43(7):1447.

196.        Liu K, Kurien BT, Zimmerman SL, et al. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjogren’s Syndrome. Arthritis & rheumatology (Hoboken, NJ). 2016;68(5):1290-1300.

197.        Legendre M, Devilliers H, Perard L, et al. Clinicopathologic characteristics, treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults: A national retrospective strobe-compliant study. Medicine. 2016;95(26):e3964.

198.        Lahaye C, Soubrier M, Mulliez A, et al. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology (Oxford, England). 2016;55(5):874-882.

199.        Kowalczyk-Quintas C, Schuepbach-Mallepell S, Vigolo M, et al. Antibodies That Block or Activate Mouse B Cell Activating Factor of the Tumor Necrosis Factor (TNF) Family (BAFF), Respectively, Induce B Cell Depletion or B Cell Hyperplasia. The Journal of biological chemistry. 2016;291(38):19826-19834.

200.        Jung S, Schickel JN, Kern A, et al. Chronic bacterial infection activates autoreactive B cells and induces isotype switching and autoantigen-driven mutations. European journal of immunology. 2016;46(1):131-146.

201.        Harris VM, Sharma R, Cavett J, et al. Klinefelter’s syndrome (47,XXY) is in excess among men with Sjogren’s syndrome. Clinical immunology (Orlando, Fla). 2016;168:25-29.

202.        Harifi G, Sibilia J. Pathogenic role of platelets in rheumatoid arthritis and systemic autoimmune diseases. Perspectives and therapeutic aspects. Saudi medical journal. 2016;37(4):354-360.

203.        Hachulla E, Hatron PY, Carpentier P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Annals of the rheumatic diseases. 2016;75(6):1009-1015.

204.        Guffroy A, Dima A, Nespola B, et al. Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. Joint, bone, spine : revue du rhumatisme. 2016;83(3):330-334.

205.        Grimbacher B, Warnatz K, Yong PFK, Korganow AS, Peter HH. The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects. The Journal of allergy and clinical immunology. 2016;137(1):3-17.

206.        Gottenberg JE, Brocq O, Perdriger A, et al. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. Jama. 2016;316(11):1172-1180.

207.        Gardette A, Ottaviani S, Sellam J, et al. Body mass index and response to abatacept in rheumatoid arthritis. European journal of clinical investigation. 2016;46(12):1048-1052.

208.        Fodil D, Meyer A, Salah SS, Sibilia J, Attal N, Tafiani-Lefkir S. Universalis Calcinosis in Adult Dermatomyositis: An “Anti-NXP2 Syndrome”. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2016;22(7):387-389.

209.        Crickx E, Machelart I, Lazaro E, et al. Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A French Nationwide Study of Ninety-Two Patients. Arthritis & rheumatology (Hoboken, NJ). 2016;68(3):702-712.

210.        Collange O, Wolff V, Cebula H, et al. Spontaneous Intracranial Hypotension: An Etiology for Consciousness Disorder and Coma. A & A case reports. 2016;7(10):207-211.

211.        Chasset F, Barete S, Charlotte F, et al. Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. Journal of the American Academy of Dermatology. 2016;74(3):513-520.

212.        Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Frances C. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. Journal of the American Academy of Dermatology. 2016;74(4):693-699.e693.

213.        Carvajal Alegria G, Guellec D, Mariette X, et al. Epidemiology of neurological manifestations in Sjogren’s syndrome: data from the French ASSESS Cohort. RMD open. 2016;2(1):e000179.

214.        Brito-Zeron P, Theander E, Baldini C, et al. Early diagnosis of primary Sjogren’s syndrome: EULAR-SS task force clinical recommendations. Expert review of clinical immunology. 2016;12(2):137-156.

215.        Boissier R, Magalon J, Sabatier F, et al. Histological and Urodynamic Effects of Autologous Stromal Vascular Fraction Extracted from Fat Tissue with Minimal Ex Vivo Manipulation in a Porcine Model of Intrinsic Sphincter Deficiency. The Journal of urology. 2016;196(3):934-942.

216.        Berthelot JM, Sibilia J. Rampant infections of bone marrow stem cell niches as triggers for spondyloarthropathies and rheumatoid arthritis. Clinical and experimental rheumatology. 2016;34(2):329-336.

217.        Beck M, Michel B, Rybarczyk-Vigouret MC, et al. Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2016;30(6):585-592.

218.        Azzouz DF, Martin GV, Arnoux F, et al. Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. PloS one. 2016;11(9):e0160283.

219.        Alsaleh G, Nehmar R, Bluml S, et al. Reduced DICER1 Expression Bestows Rheumatoid Arthritis Synoviocytes Proinflammatory Properties and Resistance to Apoptotic Stimuli. Arthritis & rheumatology (Hoboken, NJ). 2016;68(8):1839-1848.

220.        Allenbach Y, Leroux G, Suarez-Calvet X, et al. Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: Common Interferon Signature but Distinct NOS2 Expression. The American journal of pathology. 2016;186(3):691-700.

221.        Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain : a journal of neurology. 2016;139(Pt 8):2131-2135.

222.        Viguier M, Rist S, Aubin F, et al. Online training on skin cancer diagnosis in rheumatologists: results from a nationwide randomized web-based survey. PloS one. 2015;10(5):e0127564.

223.        Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Annals of the rheumatic diseases. 2015;74(5):859-866.

224.        Seror R, Le Gall-David S, Bonnaure-Mallet M, et al. Association of Anti-Porphyromonas gingivalis Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, NJ). 2015;67(7):1729-1737.

225.        Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjogren’s syndrome disease activity index (ESSDAI): a user guide. RMD open. 2015;1(1):e000022.

226.        Saraux A, Benichou J, Guillevin L, et al. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-alpha antagonists in France? The CORPUS cohort study. Clinical and experimental rheumatology. 2015;33(5):602-610.

227.        Ruer-Laventie J, Simoni L, Schickel JN, et al. Overexpression of Fkbp11, a feature of lupus B cells, leads to B cell tolerance breakdown and initiates plasma cell differentiation. Immunity, inflammation and disease. 2015;3(3):265-279.

228.        Rey D, Treger M, Sibilia J, et al. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART. Infectious diseases (London, England). 2015;47(2):88-95.

229.        Ramos-Casals M, Brito-Zeron P, Seror R, et al. Characterization of systemic disease in primary Sjogren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford, England). 2015;54(12):2230-2238.

230.        Meyer A, Sibilia J, Geny B. In the idiopathic inflammatory myopathies, reactive oxygen species are at the crossroad between immune and non-immune cell-mediated mechanisms. Annals of the rheumatic diseases. 2015;74(11):e62.

231.        Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford, England). 2015;54(1):50-63.

232.        Meyer A, Lefevre G, Bierry G, et al. In antisynthetase syndrome, ACPA are associated with severe and erosive arthritis: an overlapping rheumatoid arthritis and antisynthetase syndrome. Medicine. 2015;94(20):e523.

233.        Meyer A, Lannes B, Carapito R, et al. Eosinophilic myositis as first manifestation in a patient with type 2 myotonic dystrophy CCTG expansion mutation and rheumatoid arthritis. Neuromuscular disorders : NMD. 2015;25(2):149-152.

234.        Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients. Circulation. 2015;132(18):1693-1700.

235.        Lefevre G, Meyer A, Launay D, et al. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology (Oxford, England). 2015;54(5):927-932.

236.        Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(5):411-418.

237.        Guffroy A, Helali M, Merle B, Imperiale A, Chatelus E. Chloroma–an uncommon cause of arthritis. Arthritis & rheumatology (Hoboken, NJ). 2015;67(8):2239.

238.        Granel B, Daumas A, Jouve E, et al. Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial. Annals of the rheumatic diseases. 2015;74(12):2175-2182.

239.        Gossec L, Danre A, Combe B, et al. Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients. Joint, bone, spine : revue du rhumatisme. 2015;82(6):451-454.

240.        Francois A, Gombault A, Villeret B, et al. B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. Journal of autoimmunity. 2015;56:1-11.

241.        Eap S, Morand D, Clauss F, et al. Nanostructured thick 3D nanofibrous scaffold can induce bone. Bio-medical materials and engineering. 2015;25(1 Suppl):79-85.

242.        Dougados M, Soubrier M, Perrodeau E, et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Annals of the rheumatic diseases. 2015;74(9):1725-1733.

243.        Dorgham K, Amoura Z, Parizot C, et al. Ultraviolet light converts propranolol, a nonselective beta-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. European journal of immunology. 2015;45(11):3174-3187.

244.        Dieval C, Deligny C, Meyer A, et al. Myocarditis in Patients With Antisynthetase Syndrome: Prevalence, Presentation, and Outcomes. Medicine. 2015;94(26):e798.

245.        Devilliers H, Amoura Z, Besancenot JF, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford, England). 2015;54(5):940-949.

246.        Devauchelle-Pensec V, Gottenberg JE, Jousse-Joulin S, et al. Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjogren’s Syndrome? PloS one. 2015;10(9):e0133907.

247.        Courties A, Grateau G, Philippe P, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2015;22(2):84-92.

248.        Cornec D, Devauchelle-Pensec V, Mariette X, et al. Development of the Sjogren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford, England). 2015;54(9):1699-1708.

249.        Chasset F, Frances C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. Journal of the American Academy of Dermatology. 2015;72(4):634-639.

250.        Chasset F, Frances C, Arnaud L. Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus. Journal of the American Academy of Dermatology. 2015;73(2):e81.